Vaccine Design
In the Vaccine Design category, we highlight our pioneering efforts in creating innovative vaccines through advanced bioinformatics and cutting-edge biotechnology. Our research focuses on developing vaccines that address some of the most pressing global health challenges. By leveraging state-of-the-art techniques and collaborative expertise, we aim to deliver vaccines with exceptional efficacy and safety profiles. This category showcases our commitment to advancing vaccine technology, with a particular emphasis on our efforts to develop vaccines against emerging infectious diseases.
Development of SARS-CoV-2 vaccine (Candidate 1 and 2)
Helix Biogen Institute, also known as Helix Biogen Consult, and Thelvax have come together to develop a vaccine candidate for COVID-19. The vaccine contains an antigenic component of the surface glycoprotein of SARS-CoV-2, which has been expressed in E. coli. Animal trials are currently being conducted for the vaccine at the Helix Biogen Institute Laboratory. This vaccine is expected to play a significant role in eradicating SARS-CoV-2 in the near future. The vaccine being developed by Helix Biogen Institute and Thelvax uses insect cell-based protein expression to produce antigenic components of the surface glycoprotein of SARS-CoV-2. This method is cost-effective and has the ability to preserve the antigenic, immunogenic, and functional properties of mammalian proteins. The vaccine is currently undergoing animal testing.
Lassa virus vaccine (Candidate 1, 2 and 3)
The Helix Biogen Institute is currently in the process of developing a vaccine to prevent Lassa fever in Western Africa. This vaccine includes nucleoprotein and surface glycoprotein components of the Lassa virus, and utilizes adjuvant-formulated virus-like particles to induce antibodies with broad neutralizing activity. The vaccine is currently awaiting animal trials, but has the potential to significantly reduce the occurrence of Lassa fever. Additionally, the institute is also working on the development of another Lassa virus vaccine that contains only nucleotide proteins, which is also currently under development and awaiting animal trials.
Hepatitis E vaccine (HEV)
Hepatitis E virus is a significant cause of viral hepatitis that spreads through contaminated water. It poses a considerable risk to public health globally, especially in developing countries. The Helix Biogen Institute Laboratory is developing a vaccine to prevent future infections. Currently, the vaccine is awaiting animal trials.
Breast Cancer Vaccine
Breast cancer is a serious concern that mostly affects women. The available medicines have limited effectiveness in stopping the growth of cancer cells. Therefore, developing a multi-epitope vaccine candidate can provide a feasible approach for successful immunotherapy against cancerous cells.
Nipah Virus Vaccine
The Nipah virus is a dangerous illness that can spread from bats to humans and animals. To prevent it from becoming a widespread pandemic, a vaccination is necessary. Scientists have come up with a new approach that combines biological systems with data-driven prediction tools to study the immune response. This method involves using bioinformatics to predict T and B cells, along with an agent-based simulator of the immune response. The vaccine construct is currently being further tested using in vitro and in vivo approaches.